CN110433177A - A kind of DHA algal fat capsule and preparation method thereof - Google Patents
A kind of DHA algal fat capsule and preparation method thereof Download PDFInfo
- Publication number
- CN110433177A CN110433177A CN201910788359.2A CN201910788359A CN110433177A CN 110433177 A CN110433177 A CN 110433177A CN 201910788359 A CN201910788359 A CN 201910788359A CN 110433177 A CN110433177 A CN 110433177A
- Authority
- CN
- China
- Prior art keywords
- parts
- dha algal
- test
- dha
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002775 capsule Substances 0.000 title claims abstract description 58
- 238000002360 preparation method Methods 0.000 title claims abstract description 34
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 78
- 239000007901 soft capsule Substances 0.000 claims abstract description 45
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 44
- 235000019198 oils Nutrition 0.000 claims abstract description 36
- 235000021323 fish oil Nutrition 0.000 claims abstract description 33
- 235000013871 bee wax Nutrition 0.000 claims abstract description 29
- 239000012166 beeswax Substances 0.000 claims abstract description 29
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims abstract description 25
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims abstract description 25
- 239000008213 purified water Substances 0.000 claims abstract description 25
- 108010010803 Gelatin Proteins 0.000 claims abstract description 24
- 229920000159 gelatin Polymers 0.000 claims abstract description 24
- 239000008273 gelatin Substances 0.000 claims abstract description 24
- 235000019322 gelatine Nutrition 0.000 claims abstract description 24
- 235000011852 gelatine desserts Nutrition 0.000 claims abstract description 24
- 238000004040 coloring Methods 0.000 claims abstract description 22
- 239000003292 glue Substances 0.000 claims description 19
- 239000007788 liquid Substances 0.000 claims description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- 238000003756 stirring Methods 0.000 claims description 14
- 239000004615 ingredient Substances 0.000 claims description 11
- 238000001035 drying Methods 0.000 claims description 10
- 238000002844 melting Methods 0.000 claims description 9
- 230000008018 melting Effects 0.000 claims description 9
- 235000019441 ethanol Nutrition 0.000 claims description 7
- 230000036760 body temperature Effects 0.000 claims description 6
- 238000005453 pelletization Methods 0.000 claims description 6
- 238000004321 preservation Methods 0.000 claims description 6
- 238000012545 processing Methods 0.000 claims description 6
- 238000004513 sizing Methods 0.000 claims description 6
- 238000004140 cleaning Methods 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- 238000007493 shaping process Methods 0.000 claims description 5
- 238000013461 design Methods 0.000 claims description 4
- 241000195493 Cryptophyta Species 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims 1
- 238000012360 testing method Methods 0.000 abstract description 138
- 241001465754 Metazoa Species 0.000 abstract description 28
- 238000002474 experimental method Methods 0.000 abstract description 17
- 238000000034 method Methods 0.000 abstract description 15
- 230000006386 memory function Effects 0.000 abstract description 13
- 230000006870 function Effects 0.000 abstract description 9
- 238000003908 quality control method Methods 0.000 abstract description 3
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 134
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 68
- 229940090949 docosahexaenoic acid Drugs 0.000 description 67
- 241000699666 Mus <mouse, genus> Species 0.000 description 41
- 239000003921 oil Substances 0.000 description 31
- 235000019197 fats Nutrition 0.000 description 30
- 239000000047 product Substances 0.000 description 24
- 230000009191 jumping Effects 0.000 description 19
- 230000000052 comparative effect Effects 0.000 description 17
- 230000000694 effects Effects 0.000 description 14
- 238000012549 training Methods 0.000 description 13
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 229910052802 copper Inorganic materials 0.000 description 10
- 239000010949 copper Substances 0.000 description 10
- 230000005611 electricity Effects 0.000 description 10
- 238000012856 packing Methods 0.000 description 10
- 239000002994 raw material Substances 0.000 description 10
- 238000011049 filling Methods 0.000 description 9
- 238000003860 storage Methods 0.000 description 9
- 238000011534 incubation Methods 0.000 description 8
- 230000035611 feeding Effects 0.000 description 7
- 238000010171 animal model Methods 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 235000013402 health food Nutrition 0.000 description 6
- 238000007689 inspection Methods 0.000 description 6
- 239000000084 colloidal system Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000009182 swimming Effects 0.000 description 5
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 4
- 230000035045 associative learning Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000035614 depigmentation Effects 0.000 description 4
- 230000009189 diving Effects 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- -1 Acyl serine Chemical compound 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000013016 learning Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000011574 phosphorus Substances 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 235000019483 Peanut oil Nutrition 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000004641 brain development Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000013401 experimental design Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000006993 memory improvement Effects 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 230000001473 noxious effect Effects 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000000312 peanut oil Substances 0.000 description 2
- 238000012797 qualification Methods 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 2
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 2
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 description 1
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 description 1
- YUFFSWGQGVEMMI-JLNKQSITSA-N (7Z,10Z,13Z,16Z,19Z)-docosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCCC(O)=O YUFFSWGQGVEMMI-JLNKQSITSA-N 0.000 description 1
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 235000021294 Docosapentaenoic acid Nutrition 0.000 description 1
- 239000000940 FEMA 2235 Substances 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- 206010016946 Food allergy Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000282373 Panthera pardus Species 0.000 description 1
- 240000007509 Phytolacca dioica Species 0.000 description 1
- 229920001617 Vinyon Polymers 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 235000008452 baby food Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 239000000571 coke Substances 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 238000005485 electric heating Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000012212 insulator Substances 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 235000021388 linseed oil Nutrition 0.000 description 1
- 239000000944 linseed oil Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 238000011169 microbiological contamination Methods 0.000 description 1
- 239000012768 molten material Substances 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 125000001095 phosphatidyl group Chemical group 0.000 description 1
- 150000008106 phosphatidylserines Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000020509 sex determination Effects 0.000 description 1
- 235000013322 soy milk Nutrition 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L21/00—Marmalades, jams, jellies or the like; Products from apiculture; Preparation or treatment thereof
- A23L21/20—Products from apiculture, e.g. royal jelly or pollen; Substitutes therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/60—Fish, e.g. seahorses; Fish eggs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
The present invention relates to soft capsule technical fields, more particularly to a kind of DHA algal fat capsule, based on following parts by weight, including 5-10 parts of DHA algal oil, 15-20 parts of fish oil, 3-6 parts of phosphatidylserine, 0.5-1.0 parts of beeswax, 20-30 parts of gelatin, 20-30 parts of purified water, 10-15 parts of glycerol, 0.5-1.0 parts of burnt sugar coloring.The present invention through animal function test and bodily fuctions' test-meal experiments have shown that, the present invention has exact auxiliary improving memory function.The present invention uses Modern preparations technique, is made under reasonable method of quality control and stringent management of product measure, and quality is stable, convenient to take.
Description
Technical field
The present invention relates to soft capsule technical fields, and in particular to a kind of DHA algal fat capsule and preparation method thereof.
Background technique
Current product mainly supplements precursors of neurotransmitters, reinforces its receptor or reduces its metabolism.But neurotransmitter and
The widely distributed organs various in vivo of receptor and tissue, side effect brought by these products is also systemic.Therefore exist
On the basis of understanding the essence of these diseases, research and development are effectively and the health care product of low side effect is extremely urgent.And China's health food
Industry development is rapid, and new resource food becomes the hot spot of modern study.
DHA, docosahexaenoic acid are commonly called as docosapentaenoic acid, are a kind of pair of very important polyunsaturated fatty acids of human body, belong to
Important member in Omega-3 unsaturated fatty acid family.And there is great mass of data to show containing docosahexaenoic acid
(DHA) health food has effects that enhancing is immune and auxiliary improvement of memory power, meanwhile, DHA algal oil central nervous system,
The important physiological function of cardiovascular system and visual system etc., DHA is as long-chain unsaturated fatty acid, in biomembrane
The increase of middle content can generate certain influence to the mobility, the passability of substance, receptor active of film, and the life of film can be improved
Function is managed, is conducive to the transmitting for enhancing nerve information, enhances the activity of brain and nervous system, is had to maintenance brain development, function
Very important effect.DHA can also inhibit the generation, growth and transfer of cancer, and by inhibiting proinflammatory inflammation factor to generate,
Adhesion molecule expression is adjusted to adjust immune function, has obtained extensive social recognition, the multinational DHA of regulation in the world can be used as battalion
It supports hardening agent and food additives uses.Currently, DHA has been used for infant food, dairy products, beverage, soymilk and edible oil
Rouge etc., the market demand is very big, so the production of DHA has become development trend.
Meanwhile it disclosing much improve human body or animal about by adding a certain amount of DHA algal oil in the prior art
Memory capability, and have certain effect, but individually influence of the DHA algal oil to memory capability is limited, therefore, in DHA algal
Further increasing on the basis of oil improves the technical issues of memory capability is current urgent need to resolve.
Patent application CN107836717A discloses a kind of with the algae oil DHA soft capsule for improving memory and its preparation side
Method is made of the raw material of following parts by weight: 20-35 parts of DHA algal oil, 40-60 parts of gelatin, and 50-75 parts of purified water, glycerol 10-18
Part, it is protected from light 2-5 parts of agent, 1.2-2.8 parts of preservative.Design is scientific and reasonable for the invention, can control capsule shells well hardness
And flexibility, but can also further be promoted in the performance of the stability of product and improvement memory.
Patent application CN 109259236A discloses a kind of can enhance and remembers, improves intelligence DHA algal fat capsule, including
Sandwich and crust, wherein described sandwich including edible glucose, DHA algal oil, linseed oil, taurine, nutrient powder；The crust
Including edible glucose, edible gelatin, glycerol, D-sorbite, citric acid, water.The present invention have promote brain development, growth and
The effect of strengthen immunity achievees the effect that enhancing memory, improves intelligence.
In addition, during preparing soft capsule using DHA algal oil, it is easy to appear that preparation process is many and diverse, waste is serious, raw
Produce that low efficiency, yield rate be low and the problem of final product quality stability difference.The especially preparation process of ingredient, colloidal sol and pelleting
The unreasonable of middle experiment condition will cause that yield rate is low, and the problem of stability difference.
Patent application CN108477601A discloses the preparation method of DHA algal fat capsule, by ingredient, molten material, colloidal sol,
Techniques such as pelleting, sizing, drying and packaging, detection, storage etc. are made, and whole collinear processing, avoid it is unstable because
Nutrition loss caused by element reduces influence of the environment to capsule to the greatest extent, but in the patent application in each step
The setting of temperature and suction will lead to stability by a degree of influence, to influence yields.
Therefore, likewise, offer prepares the Modern preparations technique of soft capsule, reasonable method of quality control is to need now
The technical issues of solution.
Summary of the invention
The present invention is directed to overcome the shortcomings of in existing soft capsule and application technology, a kind of DHA algal fat capsule is proposed
And preparation method thereof.
On the one hand, a kind of DHA algal fat capsule, based on following parts by weight, including 5-10 parts of DHA algal oil, fish oil 15-20
Part, 3-6 parts of phosphatidylserine, 20-30 parts of gelatin, 20-30 parts of purified water, 10-15 parts of glycerol, 0.5-1.0 parts of burnt sugar coloring.
Further, the phosphatidylserine sieves with 100 mesh sieve.
It further, further include 0.5-1.0 parts of beeswax.
Further, based on following parts by weight, including 6-8 parts of DHA algal oil, 18-20 parts of fish oil, phosphatidylserine 4-6
Part, 0.5-0.7 parts of beeswax, 26-28 parts of gelatin, 25-28 parts of purified water, 12-14 parts of glycerol, 0.8-1.0 parts of burnt sugar coloring.
On the other hand, the present invention provides a kind of preparation method of DHA algal fat capsule, include the following steps；
(1) fish oil, phosphatidylserine, DHA algal oil, beeswax ingredient: are taken；The fish oil of 45-55% is heated to 48-52
DEG C, beeswax melting is added；It is cooled to 38-42 DEG C, DHA algal oil and remaining fish oil is added, is uniformly mixed, adds phosphatidyl silk
Propylhomoserin stirring, grinds, filtering；It vacuumizes；Bubble is taken off, content feed liquid is made, for use；
(2) colloidal sol: taking purified water, glycerol, burnt sugar coloring, purified water be first heated to 70-80 DEG C, adds glycerol, caramel
Color is added gelatin after stirring, vacuumizes, and takes off bubble, filtering, and 60 ± 5 DEG C of heat preservations obtain required glue, for use；
(3) pelleting: prepared content feed liquid and glue are suppressed into pelletization, control 60 ± 5 DEG C of temperature, sprinkler body temperature
37-42 DEG C, humidity is less than 45%；
(4) it is formed: the soft capsule suppressed is carried out shaping into processing.
Further, setting treatment design parameter in the step (4) are as follows: 18-26 DEG C of temperature, humidity is done less than 45%
It is 4-5 hours dry.
Further, further comprising the steps of: to wash ball；Soft capsule after sizing is washed into ball with ethyl alcohol, removes soft capsule table
Face spot.
Further, the ethyl alcohol that ethyl alcohol is 95%.
Further, further comprising the steps of: dry；Soft capsule after cleaning is transferred to drying room, controls temperature 18-26
DEG C, relative humidity is 22-28 hours dry less than 35%.
Further, the range that vacuumizes in the step (1) and step (2) is -0.08~-0.06Mpa.
Further, the filtering in the step (1) and step (2) uses 100 meshes.
Further, the present invention also provides selecting ball, inner packing, outer packing, examine storage, and strict control is raw
Each of production process link with liquid, colloidal sol, pelleting, washes ball, drying, selects ball, packaging material stock into the material of clean area
Between be 100,000 grades purification.
Further, of the invention to select ball step, including choose inclined ball, leakage ball, remove substandard product.
Further, inner packing step of the invention, including soft capsule is sealed loaded in PET plastic bottle.Per bottled 60
Grain.
Further, outer packing step of the invention, including labelling, mounted box, vanning.
Further, inspection of the invention storage, is that items quality index as defined in this product is examined item by item respectively, qualified
Afterwards, it affixes one's seal storage.
Soft capsule dosage form provided by the invention is relatively suitble to the filling of oils drug, can be with due to the leakproofness of its cyst membrane
Air is blocked, the stability of raw material is increased, and poor taste can be covered well, has been more convenient taking for patient.
Compared with prior art, the invention has the benefit that
(1) present invention through animal function test and bodily fuctions' test-meal experiments have shown that, the present invention has the improvement of exact auxiliary
Memory function.
(2) the present invention provides DHA algal oil, fish oil, phosphatidylserines as principal component, and has collaboration between three
Effect, can improve memory function, the product is effective and side effect is low.
(3) soft capsule provided by the invention uses Modern preparations technique, in reasonable method of quality control and strictly
It is made under management of product measure, quality is stable, convenient to take.
(4) in preparation method provided by the invention, the heating temperature twice provided in batching step makes the steady of capsule
It is qualitative good；Suction provided by the invention further improves the stability of capsule simultaneously.
(5) the supplementary material ingredient of soft capsule provided by the invention is non-easy microbiological contamination ingredient, it is ensured that the quality of product.
(6) when fish oil provided by the invention is mixed with beeswax, melting temperature can be reduced, that is to say, that temperature is not up to 62-
67 DEG C (melting temperature of beeswax), beeswax begins to dissolution.
Detailed description of the invention
Fig. 1 is water maze device schematic diagram；
Mark: where B at A, training in first day, S, starting point are trained at training in second day
E1, E2, E3, E4 are respectively G, ladder at mistake
Specific embodiment
Below with reference to specific embodiment, the technical scheme of the present invention will be further described, but claimed range is simultaneously
It is not limited to this.
A kind of DHA algal fat capsule of embodiment 1 and preparation method thereof
A kind of DHA algal fat capsule, based on following parts by weight, by 8 parts of DHA algal oil, 20 parts of fish oil, phosphatidylserine 6
Part, 28 parts of gelatin, 28 parts of purified water, 14 parts of glycerol, 1.0 parts of burnt sugar coloring, 0.6 part of beeswax composition.Wherein, phosphatidylserine mistake
100 meshes.
A kind of preparation method of DHA algal fat capsule: the following steps are included: (1) ingredient: weighing fish oil, phosphorus by formula ratio
Acyl serine, DHA algal oil, beeswax；50% fish oil is heated to 50 DEG C, beeswax melting is added；40 DEG C are cooled to, is added
The fish oil of DHA algal oil and residue 50% is uniformly mixed, and is added phosphatidylserine and is stirred 30 minutes, feed liquid crosses colloid barreling
Mill 3 times, 100 mesh screens；It vacuumizes (- 0.07Mpa) and takes off bubble, content feed liquid is made, for use；(2) colloidal sol: by formula
Amount weighs gelatin, purified water, glycerol, burnt sugar coloring, and purified water is first heated to 75 DEG C, adds glycerol, burnt sugar coloring, stirs 30 points
Gelatin is added after clock, continues stirring 1 hour, vacuumizes (- 0.07Mpa) and takes off bubble, 100 mesh screens, 60 DEG C of heat preservations obtain
Required glue, for use；(3) pelleting: prepared content feed liquid and glue being set and suppress pelletization on encapsulating machine, control glue
Box temperature 60 C, 40 DEG C of sprinkler body temperature, humidity 40%, every dress 0.6g of content；(4) it is formed: the soft capsule that will be suppressed
Carry out shaping processing (temperature is 22 DEG C, and humidity 38% is 4 hours dry).(5) ball is washed: by the soft capsule after sizing with 95%
Ethyl alcohol washes ball, removes soft capsule surface blot.(6) dry: the soft capsule after cleaning is transferred to drying room, controls 22 DEG C of temperature,
Relative humidity is 24 hours dry less than 30%, and the soft capsule after drying is without viscous tide sense.(7) it selects ball: choosing inclined ball, leakage ball, remove
Substandard product.(8) it inner packing: by soft capsule loaded in PET plastic bottle, seals.Per bottled 60.(9) outer packing: labeling
Label, mounted box, vanning.(10) examine storage: examined item by item respectively by item quality index as defined in this product, qualification after, affix one's seal into
Library.
A kind of DHA algal fat capsule of embodiment 2 and preparation method thereof
A kind of DHA algal fat capsule, based on following parts by weight, by 10 parts of DHA algal oil, 19 parts of fish oil, phosphatidylserine 5
Part, 20 parts of gelatin, 20 parts of purified water, 10 parts of glycerol, 0.9 part of burnt sugar coloring, 0.7 part of beeswax composition.Wherein, phosphatidylserine mistake
100 meshes.
A kind of preparation method of DHA algal fat capsule: the following steps are included: (1) ingredient: weighing fish oil, phosphorus by formula ratio
Acyl serine, DHA algal oil, beeswax；45% fish oil is heated to 52 DEG C, beeswax melting is added；38 DEG C are cooled to, is added
The fish oil of DHA algal oil and residue 55% is uniformly mixed, and is added phosphatidylserine and is stirred 30 minutes, feed liquid crosses colloid barreling
Mill 3 times, 100 mesh screens；It vacuumizes (- 0.06Mpa) and takes off bubble, content feed liquid is made, for use；(2) colloidal sol: by formula
Amount weighs gelatin, purified water, glycerol, burnt sugar coloring, and purified water is first heated to 70 DEG C, adds glycerol, burnt sugar coloring, stirs 30 points
Gelatin is added after clock, continues stirring 1 hour, vacuumizes (- 0.08Mpa) and takes off bubble, 100 mesh screens, 65 DEG C of heat preservations obtain
Required glue, for use；(3) pelleting: prepared content feed liquid and glue being set and suppress pelletization on encapsulating machine, control glue
65 DEG C of box temperature, 42 DEG C of sprinkler body temperature, humidity 38%, every dress 0.6g of content；(4) it is formed: the soft capsule that will be suppressed
Carry out shaping processing (temperature is 26 DEG C, and humidity 36% is 5 hours dry).(5) ball is washed: by the soft capsule after sizing with 95%
Ethyl alcohol washes ball, removes soft capsule surface blot.(6) dry: the soft capsule after cleaning is transferred to drying room, controls 18 DEG C of temperature,
Relative humidity is 25%, 28 hours dry, and the soft capsule after drying is without viscous tide sense.(7) it selects ball: choosing inclined ball, leakage ball, remove not
Qualified products.(8) it inner packing: by soft capsule loaded in PET plastic bottle, seals.Per bottled 60.(9) outer packing: labelling,
Mounted box, vanning.(10) it examines storage: being examined item by item respectively by items quality index as defined in this product, after qualified, storage of affixing one's seal.
A kind of DHA algal fat capsule of embodiment 3 and preparation method thereof
A kind of DHA algal fat capsule, based on following parts by weight, by 5 parts of DHA algal oil, 15 parts of fish oil, phosphatidylserine 3
Part, 0.5 part of beeswax, 30 parts of gelatin, 30 parts of purified water, 15 parts of glycerol, 0.5 part of burnt sugar coloring composition.Wherein, phosphatidylserine mistake
100 meshes.
A kind of preparation method of DHA algal fat capsule: the following steps are included: (1) ingredient: weighing fish oil, phosphorus by formula ratio
Acyl serine, DHA algal oil, beeswax；55% fish oil is heated to 48 DEG C, beeswax melting is added；42 DEG C are cooled to, is added
The fish oil of DHA algal oil and residue 45% is uniformly mixed, and is added phosphatidylserine and is stirred 30 minutes, feed liquid crosses colloid barreling
Mill 3 times, 100 mesh screens；It vacuumizes (- 0.08Mpa) and takes off bubble, content feed liquid is made, for use；(2) colloidal sol: by formula
Amount weighs gelatin, purified water, glycerol, burnt sugar coloring, and purified water is first heated to 80 DEG C, adds glycerol, burnt sugar coloring, stirs 30 points
Gelatin is added after clock, continues stirring 1 hour, vacuumizes (- 0.06Mpa) and takes off bubble, 100 mesh screens, 55 DEG C of heat preservations obtain
Required glue, for use；(3) pelleting: prepared content feed liquid and glue being set and suppress pelletization on encapsulating machine, control glue
55 DEG C of box temperature, 37 DEG C of sprinkler body temperature, humidity 38%, every dress 0.6g of content；(4) it is formed: the soft capsule that will be suppressed
Carry out shaping processing (temperature is 18 DEG C, and humidity 36% is 5 hours dry).(5) ball is washed: by the soft capsule after sizing with 95%
Ethyl alcohol washes ball, removes soft capsule surface blot.(6) dry: the soft capsule after cleaning is transferred to drying room, controls 26 DEG C of temperature,
Relative humidity is 30%, 22 hours dry, and the soft capsule after drying is without viscous tide sense.(7) it selects ball: choosing inclined ball, leakage ball, remove not
Qualified products.(8) it inner packing: by soft capsule loaded in PET plastic bottle, seals.Per bottled 60.(9) outer packing: labelling,
Mounted box, vanning.(10) it examines storage: being examined item by item respectively by items quality index as defined in this product, after qualified, storage of affixing one's seal.
Bodily fuctions' test-meal test
Auxiliary improving memory function human experiment experiment of the present invention
(1) sample: capsule No.1, No. 2, No. 3, No. 4 are provided by Guangdong Tongde Pharmaceutical Company.Four packaging,
Almost the same in appearance, color and mouthfeel, wherein capsule No.1 is the DHA algal fat capsule that the embodiment of the present invention 1 provides；Capsule 2
Number DHA algal fat capsule provided for the embodiment of the present invention 2；The capsule 3 DHA algal oil flexible glues provided for the embodiment of the present invention 3
Capsule；Capsule 4 are placebo.Oral recommended dose 2 times a day, 2 tablets each time.
(2) subject selects
Be included in standard: subject come from Shanghai City unit, the age 20-60 years old, male or female.Physical condition is good
Good, without obvious brain, the heart, liver, kidney, hematologic disease, no Long-term taking medicine history, not receiving similar test, (memory quotient, IQ are surveyed
Examination), it did not took in 1 year and remembers related drug or health food with improving, volunteer guarantees cooperation.
Exclusion criteria: gestation or newborn phase women, to health food allergy sufferers；Merge intentionally, liver, kidney and hemopoietic system etc. it is tight
Weight Disease；Article related with tested function is taken in a short time, is influenced to result judgement person；The standard of being included in is not met,
Not by edible given the test agent is provided, can not determining effect or data, umbra does not ring effect or safe sex determination person.
(3) experimental design and grouping
Using control, double blind, random design method.First time test is carried out before taking sample, is randomly divided into examination by memory quotient
Food group and control group consider the harmony for influencing principal element such as educational level, age of result etc., between guarantee group as far as possible
Comparativity, after examining two groups of memory quotients balanced, then randomly selecting three groups of groups is test group 1, test group 2, test group 3, another
Group is control group；Every group of 52 subjects；Test group 1 takes capsule No.1, and test group 2 takes capsule 2, and test group 3 takes glue
Capsule 3, control group takes capsule 4.
(4) experimental method
Test-meal group and control group take sample by recommended dose since on December 01st, 2018.It is responsible for sending out sample by special messenger
Product and supervise take.Refuse to obey during test and remember related health food or drug with improvement, does not participate in unrelated with this test
Memory quotient or IQ test.It carries out testting for second after continuously taking 45 days.
(5) efficacy measures
It is tested using Clinical Memory Test, looks into scale score with original point of each subtest after test: being directed toward memory, association is learned
It practises, image is freed recall, random shape is re-recognized, the connection of portrait feature is recalled.Each subtest scale score is added to obtain total scale score
Memory quotient is looked into total scale score.
(6) test equipment: record has direction memory and the instruction of associative learning and the tape of stimulus；Picture material, figure
As freeing recall image picture, two groups each 15, totally 30 (being divided to two sets of first, second)；Random shape re-recognizes picture, standby first time
It is opened in current goal stimulus picture 20, it is standby in current goal stimulus and to be mixed into stimulation each 20, picture when re-recognizing for the second time, totally 40
, add up to 60 pictures (being divided to two sets of first, second)；Picture is recalled in the connection of portrait feature, standby to delineate people in used black and white for the first time
Image surface 6 is opened, and is opened for the people's image surface 6 presented when recalling, and the two content is identical, and sequence is different, amounts to 12；Every portrait picture back
Face indicates the features such as surname of the portrait, occupation, hobby and (is divided to two sets of first, second).Recorder, stopwatch, recording sheet.
(7) test method and requirement
Test method: each subject is forward and backward to be tested twice by same main examiner's testing, and systematic error is reduced.
Test time point: forward and backward test twice of each subject carries out in same time point, avoids the influence of biological rhythm.
When second of test, main examiner does not see grouping list, blind test.
General requirement when test: subject is surveyed by specially trained personnel in a quiet room
Examination；In addition to subject and main examiner, avoid other people on the scene as far as possible；There are three subtests related with vision in this scale,
Indoor light, which must assure that, can see clearly stimulation picture；It excludes to influence Memory result because of hearing or dysphotia as far as possible；It must
State of mind when notably subject is tested, test need to it is normal in subject's mood, do not oppose that acceptance test, attention compare
It is carried out in the case where concentration；Whether subject is tired, and whether attention is concentrated, if cooperation, to testing whether anxiety, if has
Confidence etc. is both needed to be recorded in the homepage of recording sheet；The test request of same subject is once finished；Compare with age scale point
When compared with subtest achievement, it has to be noted that whether different subtests carried out under the identical state of mind.Every subtest achievement
Original point of check errorless can insert in original subitem.
Data statistics
This test data is measurement data, can be examined and be analyzed with t to two groups of each subtest scale scores and memory quotient.From
Body control can use paired t-test, compare the t inspection using two sample copy means between group in parallel, it is neat that the latter need to carry out variance
Property examine, variable conversion appropriate is carried out to the data of Non-Gaussian Distribution or heterogeneity of variance, wait meet normal state or variance it is neat after, use
The data of conversion carry out t inspection；If change data is not able to satisfy normal state variance still and requires together, t inspection or rank sum test are used instead；But
The logging data application rank sum test of the coefficient of variation too big (such as CW > 50%).It is counted with INSTAT, SPSS statistical software.
Result judgement
Under the premise of two groups of memory quotients are balanced before the test, the memory quotient of test-meal group is higher than control group, and difference after test-meal
There is conspicuousness, while the memory quotient after test-meal group test is higher than the memory quotient before its test, and difference has conspicuousness, it is possible to determine that
The given the test agent has the function of improving memory function.
Influence of the present invention to human body memory efficacy measures
Influence of 1 present invention of table to memory scale score is directed toward
| Before test | After test | |
| Control group | 22.27±3.49 | 23.41±4.76 |
| Test group 1 | 23.55±4.45 | 28.78±3.75*# |
| Test group 2 | 22.19±3.87 | 27.72±3.88*# |
| Test group 3 | 22.09±4.03 | 27.46±3.10*# |
* compared with the control group, 0.05 <；# is compared with itself, # < 0.05
It itself is also the subject before test；
Seen from table 1, the direction memory scale score of test group before sample is taken compared with the control group, there was no significant difference (P >
0.05)；Compared with taking the direction memory scale score of test group after sample and control group and itself taking before sample, there is significant difference (P <
0.05)。
Influence of 2 present invention of table to association's quantity of study table point
| Before test | After test | |
| Control group | 26.26±5.35 | 27.18±4.59 |
| Test group 1 | 26.09±5.12 | 34.72±3.09*# |
| Test group 2 | 27.11±5.09 | 33.85±3.01*# |
| Test group 3 | 26.37±5.28 | 33.72±3.34*# |
* compared with the control group, 0.05 <；# is compared with itself, # < 0.05
As can be seen from Table 2, taking the associative learning scale score of test group before sample compared with the control group, there was no significant difference ((P >
0.05)；Compared with taking the associative learning scale score with control group of test group after sample and itself taking before sample, there is significant difference ((P
< 0.05).
3 present invention of table frees recall the influence of scale score to image
| Before test | After test | |
| Control group | 23.34±4.85 | 23.42±4.66 |
| Test group 1 | 23.07±5.10 | 27.66±4.41*# |
| Test group 2 | 23.21±5.01 | 26.89±4.21*# |
| Test group 3 | 23.15±4.87 | 27.51±4.14*# |
* compared with the control group, 0.05 <；# is compared with itself, # < 0.05
Seen from table 3, the image for taking test group before sample frees recall scale score compared with the control group, there was no significant difference (P
>
0.05)；Take test group after sample image free recall scale score and control group and itself take before sample compared with, have aobvious
It writes sex differernce (P < 0.05).
4 present invention of table re-recognizes the influence of scale score to random shape
| Before test | After test | |
| Control group | 15.47±5.43 | 15.44±5.69 |
| Test group 1 | 15.32±4.90 | 27.66±4.41 |
| Test group 2 | 15.44±4.98 | 26.80±4.58 |
| Test group 3 | 15.29±5.24 | 26.87±4.77 |
By table 4 as it can be seen that the random shape for taking test group before sample re-recognizes scale score compared with the control group, there was no significant difference
(P > 0.05)；Take test group after sample random shape re-recognize scale score and control group and itself take before sample compared with, no conspicuousness
Difference (P > 0.05).
5 present invention of table contacts portrait feature the influence for recalling scale score
| Before test | After test | |
| Control group | 18.96±5.47 | 19.40±4.52 |
| Test group 1 | 17.95±4.88 | 26.51±4.37*# |
| Test group 2 | 18.24±4.94 | 26.22±4.41*# |
| Test group 3 | 18.55±4.23 | 26.10±4.08*# |
* compared with the control group, 0.05 <；# is compared with itself, # < 0.05
By table 5 as it can be seen that the portrait feature connection for taking test group before sample recalls scale score compared with the control group, no conspicuousness is poor
Different (P > 0.05)；Take test group after sample the connection of portrait feature recall scale score and control group and itself take before sample compared with, have
Significant difference (P < 0.05).
Influence of 6 present invention of table to memory quotient
| Before test | After test | |
| Control group | 96.74±11.48 | 98.45±11.32 |
| Test group 1 | 95.70±11.86 | 116.49±8.68*# |
| Test group 2 | 96.45±11.44 | 115.81±8.70*# |
| Test group 3 | 96.27±11.73 | 116.32±8.32*# |
* compared with the control group, 0.05 <；# is compared with itself, # < 0.05
By table 6 as it can be seen that taking the memory quotient of test group before sample compared with the control group, there was no significant difference (P > 0.05)；Take sample
The memory quotient of test group is significantly higher than control group (P < 0.05) afterwards；Test group take the memory quotient after sample be significantly higher than take sample before (P
< 0.05).
(8) depigmentation rate
After experiment in 45 days, control group, test group 1-3 respectively have 2 subjects because interruption is taken by test product or can not sentence
Disconnected effect is screened out.Last efficiency test trial population group 1-3, control group are 52, are shown in Table 7.
Table 7 tests depigmentation rate
| Group | Control group (example) | Test group 1 (example) | Test group 2 (example) | Test group 3 (example) |
| Before test-meal | 54 | 54 | 54 | 54 |
| Depigmentation number | 2 | 2 | 2 | 2 |
| Depigmentation rate | 3.70% | 3.70% | 3.70% | 3.70% |
Human feeding trial the result shows that, subject continuously took soft capsule provided by the invention after 45 days, test group 1,
Test group 2, the memory of the direction of test group 3, associative learning, image is freed recall, scale score and memory quotient are recalled in the connection of portrait feature
With control group and be improved compared with itself taking before sample, have significant difference (P < 0.05).According to " health food is examined and commented
Valence technical specification " (version in 2003) evaluation criterion, prompt the present invention to have the function of that auxiliary improves human body memory function.
Animal function test
The zoopery of auxiliary improving memory function of the present invention
(1) materials and methods
Tested material
DHA algal fat capsule, derive from Guangdong Tongde Pharmaceutical Company, this part experiment using capsule 's content into
Row, is detected through Guangzhou Disease Prevention-Control Center.
(2) experimental animal
18-22g male SPF Kunming mice is provided as subject, You Junke institute Experimental Animal Center.Experimental animal
Production licence number: SCXK- (army) 2016-005 0289652.
(3) key instrument water maze (LW- II) institute of Materia Medica,Chinese Academy of Medical Sciences mouse electric light incentive condition reflects
Diving tower Zhun Beizhenghua biological Instrument and equipments Co., Ltd
(4) animal feeding
Experimental animal feeding is 20~25 DEG C of animal house temperature range, relatively mixed to spend 40~70% in SPF grades of animal houses.It raises
Material is provided by Traditional Chinese Medicine University Of Guangzhou, production licence number: SCXK- (Guangdong) 2016-0002
(5) experimental animal is grouped
This experimental design two big group, it is respectively used to water maze laboratory, Jumping test.Every group of 20 mouse, per big group
Divide control group and test group 4 again, wherein test group 4 uses the DHA algal fat capsule (every group 10) in embodiment 1, dosage point
Not Wei 0.30g/kgBW, that is, weigh 3.0g DHA algal fat capsule sample, add peanut oil to 200mL, respectively oral stomach-filling it is low,
Middle and high dosage group mouse, stomach-filling amount are 0.2ml/10gBW, and control group gives equivalent peanut oil, once a day, continuous gavage
30 days.
Next day after last stomach-filling carries out Jumping test and water maze laboratory respectively, and records corresponding index.
(6) Jumping test
Next day starts to train after last stomach-filling.Animal is put into reaction chamber adaptation environment 3min (on platform, under platform), then
By on the copper grid in animal placing response case, the alternating current of 36v is passed to immediately.Animal is shocked by electricity, and normal reaction is to jump back to
Platform (insulator), to hide noxious stimulation.Most animals may again or repeatedly skip on copper cupboard, again rapid by electric shock
It jumps back on platform.After training is primary, animal is placed on the platform of reaction chamber, records the mistake that each mouse in 5min jumps off platform
Number and the incubation period for jumping off platform for the first time, in this, as school grade.For 24 hours or resurvey after 48h testing.Deconditioning 5
Memory, which is subsided, after it tests.
It is total to record incubation period, each mouse 3min number to be shocked by electricity and the animal shocked by electricity that each mouse first time jumps off platform
Number, while calculating the percentage (percentage that the number of animals to be shocked by electricity accounts for this group of animal number) for the animal of wrong reaction occur.
(7) water maze laboratory
Last stomach-filling next day starts to train, once a day.The mouse training time is limited to 120s, is not reached in 120s
The mouse of terminal is denoted as 120s.
Water maze swimming trunk is made of vinyon.The long 100cm of swimming trunk, width 100cm, path length 90cm in high 30cm,
Wide 90cm, high 30cm, the wide 12cm of swimming lane, swimming lane move towards fixed (such as following figure), labyrinth swimming lane depth of water 15cm, and 25 DEG C of water temperature holding ±
1 DEG C, training is primary daily, and continuous 5 days, mouse was placed near ladder (G), climbs up it automatically 3 times by training for the first time, after
Mouse is placed near ladder before training every time, climbs up it automatically once；Experiment carries out stage by stage；Depending on mouse school grade by
Step lengthens distance.First day it is trained when with plate washer, shelves extremely start to train at A.Second day from B train, this distance training
3 times, until 80% or more mouse reaches terminal (G).Trained since starting point (S) within 5th day, finally with 5 days total school grades into
Row evaluation (i.e. the number of mice reached home of each group, every mouse 5 days average errors numbers and the time reached home).It does and remembers after 1 week
Recall recession experiment.
Join Fig. 1 shown in, calculate 5 training of groups of animals and test total errors number, the total time reached home and
The total number of animals (percentage) reached home in 2min.
Jumping test and water maze laboratory carry out twice.
(8) statistical analysis technique
It is for statistical analysis with SPSS for Windows software.The difference of multiple groups measuring index uses variance analysis: right
Non-Gaussian Distribution or the data of heterogeneity of variance carry out variable conversion appropriate, or use rank sum test.The difference of counting index uses
Chi-square Test: total number of cases are less than 40 or when total number of cases are equal to or more than 40 but theoretical value occur equal to or less than 1, using definite
Probabilistic method.
(9) result judgement
Any one in the number of animals of platform is jumped off in incubation period, errors number and 3min in Jumping test as sun
Property, it is positive to can determine that this tests.In water maze laboratory, time, errors number and the animal reached home reached home
Any index is the positive in number, can be judged to this and test the positive.Any one of water maze laboratory, Jumping test experimental result sun
Property, and it is consistent (the duplicate same experiment two times result of institute is the positive) to repeat experimental result, it is possible to determine that the DHA algal oil flexible glue
Capsule auxiliary improving memory function results of animal is positive.
(10) influence of the DHA algal fat capsule to Memory Function is improved
Jumping test
First time experimental result
Table 8 is as it can be seen that in mouse Jumping test, and the mouse test incubation period of test group 4 is longer than control group, and difference has system
Meter learns meaning (P < 0.05).
8 DHA algal fat capsule of table is on the preclinical influence of mouse Jumping test
Second of experimental result
By table 9 as it can be seen that in mouse Jumping test, the mouse test incubation period of test group 4 is longer than control group, and difference has
Statistical significance (P < 0.05).
9 DHA algal fat capsule of table is on the preclinical influence of mouse Jumping test
Experimental result is consistent twice, i.e., in mouse Jumping test, the mouse test incubation period of test group 4 is longer than control
Group, and difference is statistically significant (P < 0.05),
Water maze laboratory
First time experimental result
By table 10 as it can be seen that in water maze laboratory, the time that the animal of test group 4 is reached home is longer than control group, and difference
Statistically significant (P < 0.05).
Influence of the 10 DHA algal fat capsule of table to the time of reaching home in Mice water maze experiment
Second of experimental result
By table 11 as it can be seen that in water maze laboratory, the time that the animal of test group 4 is reached home is longer than control group, and difference
Statistically significant (P < 0.05).
Influence of the 11 DHA algal fat capsule of table to the time of reaching home in Mice water maze experiment
Experimental result is consistent twice, i.e. the time that the animal of test group 4 is reached home is longer than control group, and difference has statistics
It learns meaning (P < 0.05).
After the DHA algal fat capsule (0g/kgBW, 0.30g/kgBW) of the following dosage of this experiment is fed mouse 30 days
Jumping test and water maze laboratory are carried out respectively.The results show that the Jumping test of DHA algal fat capsule middle dose group mouse is latent
Phase extends, and the time that the water maze laboratory of DHA algal fat capsule middle dose group mouse is reached home shortens.It can be with preliminary judgement
DHA algal fat capsule has the function of auxiliary improvement of memory.
Comparative example 1
A kind of soft capsule with auxiliary improving memory function, including softgel shell and the content being filled in softgel shell；It is described
Content is prepared by following raw material by weight: 8 parts of DHA algal oil, 0.7 part of beeswax；The softgel shell is by by weight
The following raw material of meter is prepared: 28 parts of gelatin, 28 parts of purified water, 14 parts of glycerol, 1.0 parts of burnt sugar coloring.
Comparative example 2
A kind of soft capsule with auxiliary improving memory function, including softgel shell and the content being filled in softgel shell；It is described
Content is prepared by following raw material by weight: 20 parts of fish oil, 0.7 part of beeswax；The softgel shell is by by weight
Following raw material be prepared: 28 parts of gelatin, 28 parts of purified water, 14 parts of glycerol, 1.0 parts of burnt sugar coloring.
Comparative example 3
A kind of soft capsule with auxiliary improving memory function, including softgel shell and the content being filled in softgel shell；It is described
Content is prepared by following raw material by weight: 6 parts of phosphatidylserine, 0.7 part of beeswax；The softgel shell is by by weight
The following raw material of amount part meter is prepared: 28 parts of gelatin, 28 parts of purified water, 14 parts of glycerol, 1.0 parts of burnt sugar coloring.
Comparative example 4
A kind of soft capsule with auxiliary improving memory function, including softgel shell and the content being filled in softgel shell；It is described
Content is prepared by following raw material by weight: 8 parts of DHA algal oil, 5 parts of fish oil, 6 parts of phosphatidylserine, beeswax
0.7 part；The softgel shell is prepared by following raw material by weight: 28 parts of gelatin, 28 parts of purified water, 14 parts of glycerol, coke
1.0 parts of fried sugar.
Detect example 1: step dow n test tests the influence to learning and memory
1, experimental animal: the qualified NIH mouse of health, half male and half female.
2, laboratory apparatus: DT-200 diving tower auto testing instrument (the glad graceful science and education equipment Co., Ltd in Shanghai).
3, experimental group: diet, while the soft capsule of feeding embodiment 1, comparative example 1-4, test dose: dosage is
5g/Kg, twice daily.Blank control group is diet, not any drug of feeding.
4, experimental method
4.1 experimental animal feedings and grouping: healthy qualification NIH mouse, random to be grouped, every group of 20 mouse, male and female are chosen
Fifty-fifty, sub-cage rearing, the weight of animals was 18 ± 2g, by the continuous feeding of above-mentioned test dose 30 days.
4.2 Jumping test
4.2.1 Jumping test principle: in an open space, the animal most of the time is living all in edge and corner
It is dynamic.One high platform is set at square space center, bottom paving is powered with copper grid, copper canopy.When animal is placed on platform
It almost jumps off platform immediately, and is explored around.If animal is shocked by electricity when jumping off platform, normal reaction is to jump
Platform is returned to hide noxious stimulation.Most animals again or may be skipped to repeatedly on copper, be snapped back again after being shocked by electricity flat
Platform.
4.2.2 Jumping test training: diving tower device is when experiment, mouse to be placed on copper grid, when copper grid are logical with long hair body
When electric, the mouse jumped on copper grid is shocked by electricity, and normal reaction is to hide electric shock to jump onto platform, and most of mouse is possible to again
It is secondary or repeatedly jump off platform and shocked by electricity, platform can be snapped back when being shocked by electricity again, is so trained.Frequency of training is every
2 days 1 time, training 15 times during stomach-filling, training carries out for 1 hour before stomach-filling.Specific training program is as follows: voltage is controlled in 36V,
Mouse is put on copper mesh, environment 3min is first adapted to, is then electrified to, after mouse is shocked by electricity, majority jumps onto platform and escapes electric shock, if
Mouse jumps off platform, contacts copper mesh simultaneously with mouse biped as electric shock, is considered as wrong reaction.After stomach-filling 30 days, formally tried
It tests.When on-test, mouse is placed on diving tower, while start the watch, records mouse the 1st time and jump off the time (i.e. electric shock volt
Phase), it records mouse in 5min and jumps off number (i.e. errors number), as memory index, take its average value, specific data are shown in Table 1.
The influence test data of 12 learning and memory of little mouse of table
| It gets an electric shock incubation period (second) | Errors number (secondary) in 5min | |
| Blank control group | 176 | 4.1 |
| Embodiment 1 | 286 | 1.4 |
| Comparative example 1 | 254 | 1.9 |
| Comparative example 2 | 249 | 1.8 |
| Comparative example 3 | 252 | 2.1 |
| Comparative example 4 | 262 | 1.7 |
Analysis of experimental results: table 12 show the influence test data to learning and memory of little mouse, and essential record is electric shock
Errors number in incubation period and 5min, the compared with blank control group it can be seen from experimental data, embodiment 1, comparative example
1-4 can make mouse electric shock prolongation of latency.In addition, embodiment 1, comparative example 1-4 can make mouse compared with blank control group
Errors number substantially reduces in 5min.In addition, embodiment 1 is more significant than the effect of comparative example 1-4.
Stability experiment
1.1 instrument
LHH-150GSP integrates medicine stability test case (upper sea blue leopard testing equipment Co., Ltd)；Electric heating forced air drying
Case (Shanghai Yiheng Scientific Instruments Co., Ltd).
1.2 reagent
Soft capsule: specification: 0.6g/, product, embodiment 2 in the embodiment obtained 1 of 1 preparation method of embodiment
Product in the embodiment obtained 2 of preparation method, the product in the embodiment obtained 3 of 3 preparation method of embodiment, it is right
The product obtained under 5 preparation method of ratio, the product obtained under 6 preparation method of comparative example.
2 methods and result
Using long term test investigate the methods of, investigate project: organoleptic requirements, physical and chemical index, microbiological indicator, it is significant at
Divide index, content uniformity.
2.1 long term test
Test sample (make by the product that obtains under embodiment 1, embodiment 2, embodiment 3,5 preparation method of comparative example, comparative example 6
The product obtained under Preparation Method), it is placed 24 months under conditions of 25 DEG C ± 2 DEG C of temperature, relative humidity 60% ± 10%, respectively
In 3 months, 6 months, 9 months, 12 months, 18 months, inspection by sampling in 24 months.Inspection project and it the results are shown in Table 13- table 17.
Long-term test results show that soft capsule is placed 24 months under the conditions of 25 ± 2 DEG C of temperature, relative humidity 60 ± 10%
Sampling is detected, and as a result compared with 0 month, indices do not have significant change, and determination data is more stable.
Comparative example 5
Unlike the preparation method of the soft capsule in embodiment 1: step (1), step (3), remaining step and implementation
Example 1 is identical, and is formulated also same as Example 1.
In step (1), fish oil, phosphatidylserine, DHA algal oil, beeswax ingredient: are weighed by formula ratio；By 50% fish
Oil is heated to 65 DEG C, and beeswax melting is added；35 DEG C are cooled to, the fish oil of DHA algal oil and residue 50% is added, is uniformly mixed, then
Phosphatidylserine is added to stir 15 minutes, feed liquid is crossed colloid mill and ground 2 times, 100 mesh screens；It is de- to vacuumize (- 0.07Mpa)
Bubble to the greatest extent, is made content feed liquid, for use；
(3) pelleting: prepared content feed liquid and glue being set and suppress pelletization on encapsulating machine, control glue box temperature 53
DEG C, 30 DEG C of sprinkler body temperature, humidity 45%, every dress 0.6g of content；
Comparative example 6
Unlike the preparation method of the soft capsule in embodiment 1: step (1), step (2), remaining step and implementation
Example 1 is identical, and is formulated also same as Example 1.
In step (1), fish oil, phosphatidylserine, DHA algal oil, beeswax ingredient: are weighed by formula ratio；By 50% fish
Oil is heated to 50 DEG C, and beeswax melting is added；40 DEG C are cooled to, the fish oil of DHA algal oil and residue 50% is added, is uniformly mixed, then
Phosphatidylserine is added to stir 20 minutes, feed liquid is crossed colloid mill and ground 2 times, 100 mesh screens；It is de- to vacuumize (- 0.04Mpa)
Bubble to the greatest extent, is made content feed liquid, for use；
In step (2), colloidal sol: gelatin, purified water, glycerol, burnt sugar coloring are weighed by formula ratio, purified water is first heated to 80
DEG C, glycerol, burnt sugar coloring are added, gelatin is added in stirring after twenty minutes, continues stirring 1 hour, vacuumizes (- 0.05Mpa) and take off
Bubble, 100 mesh screens, 65 DEG C of heat preservations obtain required glue, for use；
Claims (10)
1. a kind of DHA algal fat capsule, which is characterized in that based on following parts by weight, including 5-10 parts of DHA algal oil, fish oil 15-20
Part, 3-6 parts of phosphatidylserine, 20-30 parts of gelatin, 20-30 parts of purified water, 10-15 parts of glycerol, 0.5-1.0 parts of burnt sugar coloring.
2. a kind of DHA algal fat capsule according to claim 1, which is characterized in that the phosphatidylserine crosses 100
Mesh.
3. a kind of DHA algal fat capsule according to claim 1, which is characterized in that further include 0.5-1.0 parts of beeswax.
4. a kind of DHA algal fat capsule according to claim 3, which is characterized in that based on following parts by weight, including DHA
6-8 parts of algae oil, 18-20 parts of fish oil, 4-6 parts of phosphatidylserine, 0.5-0.7 parts of beeswax, 26-28 parts of gelatin, purified water 25-28
Part, 12-14 parts of glycerol, 0.8-1.0 parts of burnt sugar coloring.
5. a kind of preparation method of DHA algal fat capsule according to claim 3 or 4, which is characterized in that including following step
Suddenly；
(1) fish oil, phosphatidylserine, DHA algal oil, beeswax ingredient: are taken；The fish oil of 45-55% is heated to 48-52 DEG C, is added
Enter beeswax melting；It is cooled to 38-42 DEG C, DHA algal oil and remaining fish oil is added, is uniformly mixed, adds phosphatidylserine
Stirring is ground, filtering；It vacuumizes；Bubble is taken off, content feed liquid is made, for use；
(2) colloidal sol: taking purified water, glycerol, burnt sugar coloring, purified water be first heated to 70-80 DEG C, adds glycerol, burnt sugar coloring, stirs
Gelatin is added after mixing, vacuumizes, takes off bubble, filters, 60 ± 5 DEG C of heat preservations obtain required glue, for use；
(3) pelleting: prepared content feed liquid and glue are suppressed into pelletization, control 60 ± 5 DEG C of temperature, sprinkler body temperature 37-42
DEG C, humidity is less than 45%；
(4) it is formed: the soft capsule suppressed is carried out shaping into processing.
6. a kind of preparation method of DHA algal fat capsule according to claim 5, which is characterized in that in the step (4)
Setting treatment design parameter are as follows: 18-26 DEG C of temperature, humidity is 4-5 hours dry less than 45%.
7. a kind of preparation method of DHA algal fat capsule according to claim 5, which is characterized in that further include following step
It is rapid: to wash ball；Soft capsule after sizing is washed into ball with ethyl alcohol.
8. a kind of preparation method of DHA algal fat capsule according to claim 5, which is characterized in that further include following step
It is rapid: dry；Soft capsule after cleaning is transferred to drying room, controls 18-26 DEG C of temperature, relative humidity is less than 35%, dry 22-28
Hour.
9. a kind of preparation method of DHA algal fat capsule according to claim 5, which is characterized in that the step (1) and
The range that vacuumizes in step (2) is -0.08~-0.06Mpa.
10. a kind of preparation method of DHA algal fat capsule according to claim 5, which is characterized in that the step (1)
100 meshes are used with the filtering in step (2).
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910788359.2A CN110433177B (en) | 2019-08-26 | 2019-08-26 | DHA algae oil soft capsule and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910788359.2A CN110433177B (en) | 2019-08-26 | 2019-08-26 | DHA algae oil soft capsule and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110433177A true CN110433177A (en) | 2019-11-12 |
| CN110433177B CN110433177B (en) | 2021-05-04 |
Family
ID=68437623
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910788359.2A Active CN110433177B (en) | 2019-08-26 | 2019-08-26 | DHA algae oil soft capsule and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110433177B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112075625A (en) * | 2020-09-11 | 2020-12-15 | 深圳太太药业有限公司 | Composition for improving memory, soft capsule thereof and preparation method thereof |
| CN115553467A (en) * | 2022-09-22 | 2023-01-03 | 江苏海王健康生物科技有限公司 | DHA algae oil zinc taurine soft capsule and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109527124A (en) * | 2019-01-24 | 2019-03-29 | 山西潞安石圪节智华生物科技有限公司 | A kind of peony seed oil preparation and preparation method thereof improving memory |
-
2019
- 2019-08-26 CN CN201910788359.2A patent/CN110433177B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109527124A (en) * | 2019-01-24 | 2019-03-29 | 山西潞安石圪节智华生物科技有限公司 | A kind of peony seed oil preparation and preparation method thereof improving memory |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112075625A (en) * | 2020-09-11 | 2020-12-15 | 深圳太太药业有限公司 | Composition for improving memory, soft capsule thereof and preparation method thereof |
| CN115553467A (en) * | 2022-09-22 | 2023-01-03 | 江苏海王健康生物科技有限公司 | DHA algae oil zinc taurine soft capsule and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110433177B (en) | 2021-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gibney et al. | Introduction to human nutrition | |
| Koletzko et al. | Pediatric nutrition in practice | |
| Dewey et al. | Update on technical issues concerning complementary feeding of young children in developing countries and implications for intervention programs | |
| Adegun et al. | Differences in the nutritional status of young school children from public and private owned primary schools in Ekiti state, Nigeria | |
| Frood et al. | Relationship between pattern of infection and development of hypoalbuminaemia and hypo-β-lipoproteinaemia in rural Ugandan children | |
| CN110433177A (en) | A kind of DHA algal fat capsule and preparation method thereof | |
| CN105255783B (en) | Composite bacteria agent and its application in improving meat chicken production performance and broiler chicken chicken meat quality | |
| DE LANGE et al. | Assessment of nicotinic acid status of population groups | |
| CN102524776A (en) | Soft capsule health food with auxiliary memory-improving function | |
| Tsala et al. | Effects of dried olive pulp dietary supplementation on quality characteristics and antioxidant capacity of pig meat | |
| CN104543274B (en) | A kind of soft sweets containing DHA | |
| Gubernick et al. | " Resource" exchange in the biparental California mouse (Peromyscus californicus): water transfer from pups to parents. | |
| CN105494643A (en) | Algal oil DHA and phosphatidylserine (PS) mixed preparation product with memory improvement function | |
| CN103815128B (en) | High-calorie feed for establishing atherosclerotic animal model and application thereof | |
| Rutstein et al. | Effects of fat and carbohydrate ingestion in human beings on serum lipids and intracellular lipid deposition in tissue culture | |
| Karalis et al. | L-Carnitine as a diet supplement in patients with type II diabetes | |
| Kumar et al. | To identify myocardial changes in severely malnourished children: A prospective observational study | |
| CN109156545A (en) | A kind of composition and preparation method thereof with regulating blood lipid action | |
| CN103989171B (en) | A kind of anti-aging beauty-care face-nourishing soft capsules and preparation technology thereof | |
| CN105831767A (en) | Composition for enhancing immunity and resisting fatigue and preparation method and application thereof | |
| Pelletier | Severe Malnutrition: A Global Approach. | |
| PICKERING et al. | I. Growth and Metabolism in Normal Infant Rhesus Monkeys (Macaca Mulatta) | |
| Blomstrand et al. | Extent of total hydrolysis of dietary glycerides during digestion and absorption in the human | |
| Abidoye et al. | A comparative study of the weaning practices and growth pattern in 3–24 month old infants fed formula and food in Nitel Health Centers and PHC's of Mushin Local Government area of Lagos, Nigeria | |
| Chow | Effect of maternal dietary protein on anthropometric and behavioral development of the offspring |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |